Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 9OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 17Fallopian Tube Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Brain Neoplasms 10Neoplasms 9Glioblastoma 9Brenner Tumor 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Oligodendroglioma 6Gliosarcoma 6Glioma 6Breast Neoplasms, Male 6Adenocarcinoma of Lung 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Astrocytoma 5Adenocarcinoma, Bronchiolo-Alveolar 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

fludarabine 3aldesleukin 3Fluorouracil 3Cyclophosphamide 3Oxaliplatin 2Leucovorin 2Interleukin-2 2Gemcitabine 2sodium thiosulfate 1montanide ISA 51 1fludarabine phosphate 1detox adjuvant 1dehydroftorafur 1danvatirsen 1Tomography, X-Ray Computed 1Specimen Handling 1Positron-Emission Tomography 1Plicamycin 1Photography 1National Cancer Institute (U.S.) 1Mitomycin 1Microscopy, Electron 1Melphalan 1Magnetic Resonance Imaging 1MLN 8237 1Floxuridine 1Erlotinib Hydrochloride 1Electrocardiography 1Doxorubicin 1Diagnostic Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrointestinal Neoplasms × Bevacizumab × Clear all
NCT00356889 2014-05-28

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 9 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡